Ángel Sevillano

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

Gema Fernández‐Juárez, Jorge Rojas-Rivera, Anne-Els van de Logt et al. · Kidney International · 2020 · 220 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Anaesthetic depth and complications after major surgery: an international, randomised controlled trial

Timothy G. Short, Douglas Campbell, Christopher Frampton et al. · The Lancet · 2019 · 169 citations

Major Surgery, Medicine, Patient Safety +8

Eculizumab in secondary atypical haemolytic uraemic syndrome

Teresa Cavero, Cristina Rabasco, Antía López et al. · Nephrology Dialysis Transplantation · 2016 · 160 citations · Full text